Janssen gets EC approval for two new indications of Imbruvica

Janssen gets EC approval for two new indications of Imbruvica

Source: 
Pharmaceutical Business Review
snippet: 


The Janssen Pharmaceutical Companies of Johnson & Johnson has secured approval from the European Commission (EC) for two new indications of Imbruvica (ibrutinib).